Key takeaways
Xeljanz (tofacitinib) and Otezla (apremilast) are both oral medications used to treat inflammatory conditions, but they belong to different drug classes and have distinct uses and side effects. Xeljanz is a Janus kinase (JAK) inhibitor that treats various types of arthritis and ulcerative colitis by blocking a protein involved in inflammation. In contrast, Otezla is a phosphodiesterase-4 (PDE-4) inhibitor that blocks a different protein to reduce inflammation associated with psoriatic arthritis, plaque psoriasis, and mouth sores from Behçet’s disease. Xeljanz can cause serious side effects like infections, heart problems, and blood clots, while Otezla is more likely to cause nausea, diarrhea, and weight loss. Both medications are not yet available as lower-cost generics. Xeljanz is available in both immediate-release and extended-release forms. And Otezla is only available in one formulation that requires a gradual dose increase to minimize stomach-related side effects.
